| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 161 | 2023 | 15694 | 4.350 |
Why?
|
| Inflammatory Breast Neoplasms | 25 | 2023 | 509 | 2.630 |
Why?
|
| Taxoids | 32 | 2021 | 967 | 2.440 |
Why?
|
| Neoadjuvant Therapy | 53 | 2023 | 4975 | 2.330 |
Why?
|
| Receptor, ErbB-2 | 40 | 2023 | 2518 | 2.280 |
Why?
|
| Triple Negative Breast Neoplasms | 25 | 2023 | 1215 | 2.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 73 | 2023 | 15862 | 1.750 |
Why?
|
| Neoplastic Cells, Circulating | 12 | 2020 | 607 | 1.410 |
Why?
|
| Trastuzumab | 21 | 2021 | 696 | 1.360 |
Why?
|
| Paclitaxel | 38 | 2023 | 1996 | 1.340 |
Why?
|
| Mastectomy | 22 | 2023 | 1534 | 1.280 |
Why?
|
| Antineoplastic Agents, Phytogenic | 21 | 2004 | 852 | 1.260 |
Why?
|
| Maytansine | 3 | 2021 | 38 | 0.940 |
Why?
|
| Female | 208 | 2023 | 141928 | 0.930 |
Why?
|
| Pancreatectomy | 6 | 2019 | 652 | 0.920 |
Why?
|
| Middle Aged | 158 | 2023 | 86204 | 0.870 |
Why?
|
| Chemotherapy, Adjuvant | 38 | 2022 | 3890 | 0.770 |
Why?
|
| Epothilones | 4 | 2015 | 54 | 0.770 |
Why?
|
| Aged | 122 | 2023 | 70117 | 0.740 |
Why?
|
| Carcinoma, Ductal, Breast | 11 | 2019 | 1216 | 0.740 |
Why?
|
| Adult | 133 | 2021 | 77950 | 0.730 |
Why?
|
| Humans | 228 | 2023 | 261506 | 0.730 |
Why?
|
| Pancreatic Diseases | 3 | 2015 | 108 | 0.720 |
Why?
|
| Neoplasm, Residual | 4 | 2021 | 1656 | 0.700 |
Why?
|
| Bile Duct Neoplasms | 2 | 2014 | 493 | 0.650 |
Why?
|
| Neoplasm Metastasis | 41 | 2019 | 5112 | 0.650 |
Why?
|
| Cholangiocarcinoma | 2 | 2014 | 493 | 0.650 |
Why?
|
| Antineoplastic Agents | 25 | 2020 | 14289 | 0.640 |
Why?
|
| Fluorouracil | 21 | 2020 | 1944 | 0.600 |
Why?
|
| Patient Readmission | 4 | 2019 | 548 | 0.600 |
Why?
|
| Postmenopause | 1 | 2019 | 378 | 0.590 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2017 | 69 | 0.590 |
Why?
|
| Necrosis | 2 | 2020 | 580 | 0.580 |
Why?
|
| Pancreatic Neoplasms | 4 | 2017 | 5061 | 0.550 |
Why?
|
| Bone Neoplasms | 8 | 2019 | 2576 | 0.550 |
Why?
|
| Doxorubicin | 25 | 2017 | 3005 | 0.550 |
Why?
|
| Disease-Free Survival | 35 | 2021 | 10001 | 0.540 |
Why?
|
| Retrospective Studies | 63 | 2023 | 37905 | 0.520 |
Why?
|
| Overweight | 1 | 2019 | 484 | 0.520 |
Why?
|
| Survival Rate | 30 | 2020 | 12221 | 0.520 |
Why?
|
| Neoplasm Staging | 35 | 2022 | 13658 | 0.510 |
Why?
|
| Psoas Muscles | 1 | 2014 | 12 | 0.510 |
Why?
|
| Cyclophosphamide | 23 | 2020 | 3001 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2023 | 10035 | 0.510 |
Why?
|
| Metformin | 1 | 2019 | 378 | 0.500 |
Why?
|
| Risk Assessment | 13 | 2019 | 6869 | 0.500 |
Why?
|
| Lymphatic Metastasis | 12 | 2021 | 4844 | 0.500 |
Why?
|
| Carboplatin | 3 | 2014 | 823 | 0.490 |
Why?
|
| Postoperative Complications | 8 | 2019 | 5542 | 0.480 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2014 | 334 | 0.480 |
Why?
|
| Receptors, Progesterone | 9 | 2020 | 1392 | 0.470 |
Why?
|
| Prognosis | 42 | 2021 | 21713 | 0.470 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2017 | 436 | 0.470 |
Why?
|
| Lymph Nodes | 12 | 2020 | 2967 | 0.460 |
Why?
|
| Receptors, Estrogen | 11 | 2019 | 2086 | 0.460 |
Why?
|
| Pancreatic Fistula | 4 | 2019 | 99 | 0.460 |
Why?
|
| Sarcopenia | 1 | 2014 | 110 | 0.450 |
Why?
|
| Pancreaticoduodenectomy | 4 | 2019 | 690 | 0.440 |
Why?
|
| Gene Amplification | 3 | 2016 | 731 | 0.430 |
Why?
|
| Treatment Outcome | 51 | 2021 | 32848 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 24 | 2019 | 6207 | 0.430 |
Why?
|
| Antibiotics, Antineoplastic | 6 | 2001 | 726 | 0.430 |
Why?
|
| Aged, 80 and over | 41 | 2019 | 29902 | 0.420 |
Why?
|
| Anthracyclines | 9 | 2023 | 331 | 0.420 |
Why?
|
| Epithelial Cells | 2 | 2017 | 1818 | 0.410 |
Why?
|
| Prospective Studies | 27 | 2023 | 12873 | 0.410 |
Why?
|
| Vinblastine | 7 | 2001 | 453 | 0.400 |
Why?
|
| Skin | 1 | 2017 | 1259 | 0.400 |
Why?
|
| Deoxycytidine | 6 | 2018 | 1353 | 0.390 |
Why?
|
| Biomarkers, Tumor | 21 | 2020 | 10331 | 0.380 |
Why?
|
| Hepatectomy | 2 | 2014 | 1011 | 0.380 |
Why?
|
| Lung Transplantation | 4 | 2015 | 359 | 0.380 |
Why?
|
| Adipose Tissue | 1 | 2016 | 769 | 0.380 |
Why?
|
| Liver Neoplasms | 4 | 2015 | 4557 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2018 | 3251 | 0.360 |
Why?
|
| Heart Transplantation | 4 | 2019 | 908 | 0.350 |
Why?
|
| Genes, erbB-2 | 5 | 2016 | 229 | 0.350 |
Why?
|
| Follow-Up Studies | 23 | 2019 | 14889 | 0.350 |
Why?
|
| Epirubicin | 6 | 2020 | 157 | 0.340 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2017 | 1724 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2019 | 4938 | 0.340 |
Why?
|
| Capecitabine | 5 | 2017 | 388 | 0.340 |
Why?
|
| Liver Diseases | 2 | 2015 | 574 | 0.330 |
Why?
|
| Carcinoma, Lobular | 5 | 2017 | 611 | 0.330 |
Why?
|
| Time Factors | 22 | 2019 | 12926 | 0.320 |
Why?
|
| Mammaplasty | 1 | 2016 | 780 | 0.320 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2020 | 1415 | 0.310 |
Why?
|
| Drug Administration Schedule | 20 | 2017 | 3472 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 2330 | 0.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2017 | 840 | 0.300 |
Why?
|
| Risk Factors | 22 | 2019 | 17523 | 0.290 |
Why?
|
| Proportional Hazards Models | 17 | 2019 | 4988 | 0.290 |
Why?
|
| Tumor Burden | 5 | 2021 | 1987 | 0.290 |
Why?
|
| Obesity | 2 | 2019 | 2884 | 0.290 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2019 | 5178 | 0.280 |
Why?
|
| Keratins | 2 | 2017 | 330 | 0.280 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1112 | 0.270 |
Why?
|
| Case Management | 1 | 2005 | 35 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2017 | 1299 | 0.270 |
Why?
|
| Mutation | 8 | 2019 | 15179 | 0.260 |
Why?
|
| Young Adult | 24 | 2021 | 21445 | 0.260 |
Why?
|
| Feasibility Studies | 5 | 2023 | 2292 | 0.250 |
Why?
|
| Survival Analysis | 17 | 2019 | 9180 | 0.250 |
Why?
|
| Estrogen Receptor alpha | 4 | 2020 | 701 | 0.240 |
Why?
|
| Odds Ratio | 6 | 2015 | 2316 | 0.240 |
Why?
|
| Predictive Value of Tests | 11 | 2019 | 4892 | 0.240 |
Why?
|
| Bridged-Ring Compounds | 4 | 2015 | 183 | 0.230 |
Why?
|
| Male | 42 | 2019 | 123000 | 0.230 |
Why?
|
| Erythema | 2 | 2005 | 52 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2019 | 2054 | 0.220 |
Why?
|
| Neoplasms | 10 | 2017 | 15193 | 0.220 |
Why?
|
| Mastectomy, Segmental | 3 | 2018 | 1026 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 9 | 2010 | 4367 | 0.220 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2019 | 521 | 0.220 |
Why?
|
| Adenocarcinoma | 4 | 2016 | 7789 | 0.210 |
Why?
|
| Epithelial Cell Adhesion Molecule | 2 | 2020 | 35 | 0.210 |
Why?
|
| Androstadienes | 2 | 2019 | 165 | 0.210 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2019 | 674 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2023 | 1546 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 2027 | 0.210 |
Why?
|
| Incidence | 7 | 2018 | 5673 | 0.210 |
Why?
|
| Ultrasonography | 5 | 2021 | 1863 | 0.210 |
Why?
|
| Neutropenia | 9 | 2008 | 968 | 0.210 |
Why?
|
| Hand Dermatoses | 2 | 1998 | 25 | 0.210 |
Why?
|
| Foot Dermatoses | 2 | 1998 | 23 | 0.210 |
Why?
|
| Everolimus | 3 | 2019 | 415 | 0.200 |
Why?
|
| Thoracic Wall | 1 | 2023 | 183 | 0.200 |
Why?
|
| Gene Expression Profiling | 8 | 2020 | 5159 | 0.190 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 622 | 0.190 |
Why?
|
| Axilla | 6 | 2021 | 902 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2011 | 749 | 0.190 |
Why?
|
| Ketones | 1 | 2020 | 54 | 0.190 |
Why?
|
| Furans | 1 | 2020 | 104 | 0.190 |
Why?
|
| Morbidity | 3 | 2019 | 397 | 0.190 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2017 | 690 | 0.180 |
Why?
|
| Patient Selection | 6 | 2019 | 2055 | 0.180 |
Why?
|
| Amylases | 2 | 2019 | 66 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2020 | 2232 | 0.180 |
Why?
|
| Vimentin | 2 | 2020 | 253 | 0.180 |
Why?
|
| Blood Loss, Surgical | 2 | 2019 | 309 | 0.180 |
Why?
|
| Lymph Node Excision | 3 | 2017 | 1959 | 0.180 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 275 | 0.170 |
Why?
|
| Combined Modality Therapy | 10 | 2018 | 8865 | 0.170 |
Why?
|
| Cohort Studies | 12 | 2020 | 9244 | 0.170 |
Why?
|
| Postoperative Care | 3 | 2019 | 739 | 0.170 |
Why?
|
| Image-Guided Biopsy | 2 | 2019 | 327 | 0.170 |
Why?
|
| RNA, Messenger | 4 | 2020 | 6150 | 0.170 |
Why?
|
| Leukocyte Common Antigens | 2 | 2016 | 188 | 0.170 |
Why?
|
| Guanidines | 2 | 1995 | 60 | 0.160 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 7548 | 0.160 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 146 | 0.160 |
Why?
|
| Heart-Assist Devices | 2 | 2019 | 1171 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 153 | 0.160 |
Why?
|
| Body Fluids | 1 | 2019 | 125 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 1998 | 588 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 253 | 0.150 |
Why?
|
| Genes, BRCA1 | 2 | 2011 | 387 | 0.150 |
Why?
|
| Breast Neoplasms, Male | 4 | 2019 | 229 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2403 | 0.150 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2014 | 222 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2020 | 2508 | 0.150 |
Why?
|
| Bevacizumab | 3 | 2017 | 938 | 0.150 |
Why?
|
| BRCA2 Protein | 2 | 2019 | 358 | 0.150 |
Why?
|
| Breast | 6 | 2023 | 1344 | 0.150 |
Why?
|
| Tachycardia, Sinus | 1 | 2016 | 12 | 0.150 |
Why?
|
| Fatigue | 4 | 2018 | 1239 | 0.150 |
Why?
|
| Quinolones | 1 | 2018 | 160 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 423 | 0.140 |
Why?
|
| Cadherins | 1 | 2020 | 660 | 0.140 |
Why?
|
| Heart Failure | 3 | 2019 | 2516 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 115 | 0.140 |
Why?
|
| Age Factors | 6 | 2018 | 5377 | 0.140 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 2173 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2018 | 479 | 0.140 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2010 | 408 | 0.140 |
Why?
|
| Yoga | 1 | 2017 | 78 | 0.140 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 603 | 0.140 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 169 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 2315 | 0.140 |
Why?
|
| BRCA1 Protein | 2 | 2019 | 493 | 0.140 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 6009 | 0.140 |
Why?
|
| Centromere | 1 | 2015 | 97 | 0.140 |
Why?
|
| Analgesia | 1 | 2016 | 94 | 0.140 |
Why?
|
| Accidental Falls | 1 | 2017 | 142 | 0.130 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 3719 | 0.130 |
Why?
|
| Heart Diseases | 2 | 2001 | 732 | 0.130 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 166 | 0.130 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 34 | 0.130 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1995 | 101 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 53 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 4757 | 0.130 |
Why?
|
| Time-to-Treatment | 2 | 2015 | 292 | 0.130 |
Why?
|
| Fractures, Bone | 1 | 2017 | 291 | 0.130 |
Why?
|
| Pilot Projects | 5 | 2019 | 2803 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2016 | 2594 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 77 | 0.120 |
Why?
|
| Nerve Block | 1 | 2016 | 176 | 0.120 |
Why?
|
| Heart Ventricles | 2 | 2016 | 846 | 0.120 |
Why?
|
| Remission Induction | 6 | 2015 | 3569 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 586 | 0.120 |
Why?
|
| Malnutrition | 1 | 2017 | 218 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 1062 | 0.120 |
Why?
|
| Tamoxifen | 5 | 2010 | 876 | 0.120 |
Why?
|
| Imatinib Mesylate | 1 | 2018 | 1665 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2016 | 263 | 0.120 |
Why?
|
| Gene Expression | 4 | 2017 | 3570 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 1998 | 649 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 348 | 0.120 |
Why?
|
| Cause of Death | 1 | 2017 | 752 | 0.120 |
Why?
|
| Calcinosis | 1 | 2017 | 423 | 0.120 |
Why?
|
| Pain Management | 2 | 2015 | 668 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2016 | 829 | 0.110 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2015 | 168 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2005 | 447 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 502 | 0.110 |
Why?
|
| Procollagen | 1 | 2012 | 31 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2012 | 756 | 0.110 |
Why?
|
| Organ Size | 1 | 2014 | 690 | 0.110 |
Why?
|
| Radiography | 3 | 2014 | 1904 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2016 | 703 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 403 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 348 | 0.110 |
Why?
|
| Checklist | 1 | 2013 | 122 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2005 | 665 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.110 |
Why?
|
| Transplant Recipients | 1 | 2015 | 324 | 0.110 |
Why?
|
| Alopecia | 3 | 2018 | 126 | 0.110 |
Why?
|
| Ovarian Neoplasms | 5 | 2015 | 4638 | 0.110 |
Why?
|
| Operating Rooms | 1 | 2013 | 122 | 0.110 |
Why?
|
| United States | 8 | 2019 | 15433 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2012 | 65 | 0.110 |
Why?
|
| Aromatase Inhibitors | 2 | 2011 | 305 | 0.110 |
Why?
|
| Pain Measurement | 2 | 2015 | 953 | 0.110 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1910 | 0.100 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 260 | 0.100 |
Why?
|
| Carcinoma | 3 | 2011 | 2578 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2014 | 8873 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 268 | 0.100 |
Why?
|
| Heterozygote | 1 | 2015 | 1020 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2020 | 973 | 0.100 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 1143 | 0.100 |
Why?
|
| Cell Count | 3 | 2020 | 508 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2023 | 7702 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 318 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2015 | 2231 | 0.100 |
Why?
|
| Biopsy | 2 | 2017 | 3443 | 0.100 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2012 | 168 | 0.100 |
Why?
|
| Lacrimal Duct Obstruction | 2 | 2002 | 53 | 0.100 |
Why?
|
| Gastrectomy | 1 | 2014 | 451 | 0.100 |
Why?
|
| Pain, Postoperative | 1 | 2016 | 610 | 0.100 |
Why?
|
| Genes, BRCA2 | 2 | 2015 | 309 | 0.100 |
Why?
|
| Brain Neoplasms | 4 | 2015 | 4849 | 0.100 |
Why?
|
| Multidetector Computed Tomography | 1 | 2012 | 150 | 0.100 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 4298 | 0.100 |
Why?
|
| Endoscopy, Digestive System | 1 | 2012 | 202 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2015 | 769 | 0.100 |
Why?
|
| Echocardiography | 1 | 2016 | 1182 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2017 | 1555 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2017 | 1085 | 0.100 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 1323 | 0.100 |
Why?
|
| Women's Health | 1 | 2012 | 205 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 610 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 589 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 598 | 0.090 |
Why?
|
| Infusions, Intravenous | 7 | 2008 | 1382 | 0.090 |
Why?
|
| Cytokines | 5 | 2019 | 2809 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2014 | 441 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 383 | 0.090 |
Why?
|
| Lymphopenia | 1 | 2012 | 199 | 0.090 |
Why?
|
| Neoplasm Grading | 4 | 2015 | 1742 | 0.090 |
Why?
|
| Mammography | 4 | 2018 | 1010 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.090 |
Why?
|
| Regression Analysis | 4 | 2016 | 1546 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 1443 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2015 | 1171 | 0.090 |
Why?
|
| Base Sequence | 1 | 2016 | 4917 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2011 | 262 | 0.080 |
Why?
|
| Pain | 3 | 2015 | 1658 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2014 | 598 | 0.080 |
Why?
|
| Risk | 3 | 2018 | 1972 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2014 | 1678 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2022 | 341 | 0.080 |
Why?
|
| Logistic Models | 4 | 2019 | 3441 | 0.080 |
Why?
|
| Phenotype | 2 | 2017 | 6295 | 0.080 |
Why?
|
| Genomics | 2 | 2010 | 2738 | 0.080 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 550 | 0.080 |
Why?
|
| Fever | 4 | 2001 | 497 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 960 | 0.080 |
Why?
|
| Triazoles | 1 | 2011 | 617 | 0.070 |
Why?
|
| Nitriles | 1 | 2011 | 906 | 0.070 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2007 | 123 | 0.070 |
Why?
|
| Disease Management | 1 | 2012 | 1052 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2012 | 1271 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 739 | 0.070 |
Why?
|
| Antiemetics | 2 | 1998 | 125 | 0.070 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2017 | 160 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2013 | 851 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 992 | 0.070 |
Why?
|
| Operative Time | 2 | 2019 | 217 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2009 | 986 | 0.070 |
Why?
|
| Neoplasm Proteins | 3 | 2014 | 3230 | 0.070 |
Why?
|
| Disease Progression | 6 | 2016 | 6682 | 0.070 |
Why?
|
| Ultrasonography, Mammary | 2 | 2021 | 380 | 0.070 |
Why?
|
| Liver Abscess | 1 | 1985 | 36 | 0.070 |
Why?
|
| Mesentery | 1 | 1986 | 72 | 0.070 |
Why?
|
| Empyema | 1 | 1985 | 28 | 0.070 |
Why?
|
| Metaplasia | 2 | 2022 | 383 | 0.070 |
Why?
|
| Pregnancy | 4 | 2022 | 7573 | 0.070 |
Why?
|
| Quality of Life | 4 | 2023 | 4532 | 0.070 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1985 | 69 | 0.070 |
Why?
|
| Stroke Volume | 2 | 2016 | 577 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.060 |
Why?
|
| Estrone | 1 | 2004 | 31 | 0.060 |
Why?
|
| Liver | 2 | 2013 | 2961 | 0.060 |
Why?
|
| Radiotherapy | 3 | 2017 | 1824 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2019 | 1053 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2015 | 2218 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 7551 | 0.060 |
Why?
|
| Resuscitation | 1 | 1986 | 223 | 0.060 |
Why?
|
| Liposomes | 3 | 2001 | 684 | 0.060 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 2002 | 137 | 0.060 |
Why?
|
| Administration, Oral | 4 | 2019 | 1544 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2011 | 1664 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1350 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2017 | 1163 | 0.060 |
Why?
|
| Dexamethasone | 2 | 1998 | 1450 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2019 | 6100 | 0.050 |
Why?
|
| SEER Program | 1 | 2006 | 1000 | 0.050 |
Why?
|
| Lung Neoplasms | 5 | 2015 | 11538 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1046 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2009 | 3578 | 0.050 |
Why?
|
| Skin Diseases | 1 | 2005 | 349 | 0.050 |
Why?
|
| Crohn Disease | 1 | 1985 | 351 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 1290 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 435 | 0.050 |
Why?
|
| Reoperation | 2 | 2017 | 1382 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2021 | 34 | 0.050 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2001 | 57 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 2370 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2014 | 2278 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 1084 | 0.050 |
Why?
|
| Radiopharmaceuticals | 3 | 2012 | 1301 | 0.050 |
Why?
|
| Premedication | 2 | 2000 | 135 | 0.050 |
Why?
|
| Colitis | 1 | 2004 | 340 | 0.050 |
Why?
|
| Sirolimus | 2 | 2017 | 814 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 556 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 1226 | 0.050 |
Why?
|
| Proteomics | 1 | 2008 | 1380 | 0.050 |
Why?
|
| Heart | 2 | 2005 | 1223 | 0.050 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2001 | 163 | 0.050 |
Why?
|
| Texas | 3 | 2017 | 6311 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2947 | 0.050 |
Why?
|
| Etoposide | 2 | 2001 | 870 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2020 | 136 | 0.050 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 1506 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 3981 | 0.040 |
Why?
|
| Edema | 2 | 1998 | 267 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2020 | 226 | 0.040 |
Why?
|
| Preoperative Care | 2 | 2017 | 1529 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 562 | 0.040 |
Why?
|
| Family | 1 | 2023 | 736 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 14551 | 0.040 |
Why?
|
| Aurora Kinase A | 1 | 2020 | 202 | 0.040 |
Why?
|
| Lacrimal Apparatus | 1 | 2001 | 181 | 0.040 |
Why?
|
| Registries | 2 | 2018 | 2170 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 2927 | 0.040 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2000 | 111 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 1999 | 216 | 0.040 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 1998 | 82 | 0.040 |
Why?
|
| Leukopenia | 1 | 2018 | 151 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 4821 | 0.040 |
Why?
|
| Muscle Stretching Exercises | 1 | 2017 | 17 | 0.040 |
Why?
|
| Length of Stay | 2 | 2015 | 1900 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 799 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 205 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2017 | 3842 | 0.040 |
Why?
|
| Ifosfamide | 1 | 1998 | 344 | 0.040 |
Why?
|
| Drug Carriers | 1 | 1999 | 327 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 1998 | 157 | 0.040 |
Why?
|
| Actigraphy | 1 | 2017 | 54 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 85 | 0.040 |
Why?
|
| Elafin | 1 | 2017 | 34 | 0.040 |
Why?
|
| Cholesterol | 2 | 2016 | 658 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 333 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2011 | 5270 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2017 | 114 | 0.040 |
Why?
|
| Forecasting | 1 | 2010 | 694 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2017 | 83 | 0.040 |
Why?
|
| Minoxidil | 1 | 1996 | 8 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2017 | 172 | 0.040 |
Why?
|
| Systole | 1 | 2016 | 196 | 0.040 |
Why?
|
| Drainage | 1 | 2019 | 416 | 0.040 |
Why?
|
| Estrogens | 1 | 2020 | 751 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 149 | 0.030 |
Why?
|
| Signal Transduction | 4 | 2017 | 11965 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1313 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 163 | 0.030 |
Why?
|
| Complement C4 | 1 | 1995 | 15 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 583 | 0.030 |
Why?
|
| Poverty | 2 | 2015 | 471 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 1998 | 256 | 0.030 |
Why?
|
| Maryland | 1 | 2015 | 48 | 0.030 |
Why?
|
| Isoantigens | 1 | 1995 | 62 | 0.030 |
Why?
|
| Platinum Compounds | 1 | 2015 | 131 | 0.030 |
Why?
|
| Fentanyl | 1 | 2016 | 148 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 452 | 0.030 |
Why?
|
| Jews | 1 | 2015 | 59 | 0.030 |
Why?
|
| Complement C3 | 1 | 1995 | 78 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 175 | 0.030 |
Why?
|
| Clubfoot | 1 | 2014 | 24 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 479 | 0.030 |
Why?
|
| Complement Activation | 1 | 1995 | 94 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 834 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2016 | 2203 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 151 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 492 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 413 | 0.030 |
Why?
|
| Antibody Formation | 1 | 1995 | 383 | 0.030 |
Why?
|
| Pancreatitis | 1 | 1997 | 267 | 0.030 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2014 | 81 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2016 | 239 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 485 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1998 | 500 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2008 | 2307 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 1472 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1995 | 553 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1832 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2013 | 73 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1493 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 750 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2001 | 1616 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2009 | 5437 | 0.030 |
Why?
|
| Physical Examination | 1 | 2015 | 299 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 615 | 0.030 |
Why?
|
| Sarcoma | 2 | 2009 | 1725 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2000 | 918 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2015 | 167 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2015 | 380 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 627 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 550 | 0.030 |
Why?
|
| ErbB Receptors | 2 | 2011 | 2295 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2017 | 677 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2012 | 87 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 527 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2015 | 641 | 0.030 |
Why?
|
| Residual Volume | 1 | 2012 | 11 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 5539 | 0.030 |
Why?
|
| Pyridines | 1 | 2019 | 1244 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2011 | 29 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2014 | 226 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 1183 | 0.030 |
Why?
|
| Aromatase | 1 | 2011 | 56 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2012 | 204 | 0.030 |
Why?
|
| Adolescent | 5 | 2015 | 31252 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2012 | 133 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2003 | 448 | 0.030 |
Why?
|
| Polycomb-Group Proteins | 1 | 2011 | 42 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 604 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2010 | 3154 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 1062 | 0.030 |
Why?
|
| Apoptosis | 2 | 2003 | 7591 | 0.020 |
Why?
|
| Health Status | 1 | 2015 | 590 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 153 | 0.020 |
Why?
|
| Exons | 1 | 2015 | 1328 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2014 | 500 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2012 | 310 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1363 | 0.020 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2011 | 84 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 2283 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 1335 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2000 | 6550 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2011 | 160 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 392 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 1998 | 2054 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2011 | 245 | 0.020 |
Why?
|
| Recurrence | 2 | 2013 | 4758 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 577 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1274 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 106 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1997 | 1390 | 0.020 |
Why?
|
| Leucovorin | 1 | 2009 | 332 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 471 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2011 | 241 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 630 | 0.020 |
Why?
|
| Palliative Care | 1 | 2010 | 2037 | 0.020 |
Why?
|
| Cisplatin | 1 | 2015 | 2432 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2013 | 795 | 0.020 |
Why?
|
| Algorithms | 2 | 2015 | 3890 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 5767 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2009 | 286 | 0.020 |
Why?
|
| Camptothecin | 1 | 2009 | 517 | 0.020 |
Why?
|
| Communication | 1 | 2013 | 876 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 849 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 1371 | 0.020 |
Why?
|
| Medical Records | 1 | 2008 | 415 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 1479 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 691 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 771 | 0.020 |
Why?
|
| Quinazolines | 1 | 2011 | 923 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3033 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 1986 | 40 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2359 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 3203 | 0.020 |
Why?
|
| ras Proteins | 1 | 2009 | 770 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 5395 | 0.020 |
Why?
|
| Encephalitis | 1 | 1986 | 143 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 3552 | 0.020 |
Why?
|
| Diarrhea | 1 | 2008 | 686 | 0.020 |
Why?
|
| History, 18th Century | 1 | 2004 | 89 | 0.010 |
Why?
|
| Cell Division | 1 | 2008 | 2489 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2014 | 8223 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 156 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 4109 | 0.010 |
Why?
|
| DNA | 1 | 2011 | 2693 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 198 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 1165 | 0.010 |
Why?
|
| Airway Obstruction | 1 | 1986 | 261 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 5637 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 461 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 253 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1997 | 4744 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1331 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1997 | 3976 | 0.010 |
Why?
|
| Nausea | 1 | 2004 | 525 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 519 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2001 | 56 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 482 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 478 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1544 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 285 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2004 | 518 | 0.010 |
Why?
|
| Estradiol | 1 | 2004 | 748 | 0.010 |
Why?
|
| Animals | 1 | 2005 | 59536 | 0.010 |
Why?
|
| Thorax | 1 | 2001 | 213 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 2488 | 0.010 |
Why?
|
| Tears | 1 | 2001 | 181 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 1519 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2001 | 297 | 0.010 |
Why?
|
| Age of Onset | 1 | 2001 | 827 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 666 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 1038 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2000 | 4320 | 0.010 |
Why?
|
| Mesna | 1 | 1998 | 65 | 0.010 |
Why?
|
| Social Class | 1 | 2000 | 310 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1538 | 0.010 |
Why?
|
| Prednisone | 1 | 2001 | 984 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1999 | 587 | 0.010 |
Why?
|
| Fibrosis | 1 | 2001 | 793 | 0.010 |
Why?
|
| CA-125 Antigen | 1 | 1998 | 226 | 0.010 |
Why?
|
| Vincristine | 1 | 2001 | 1511 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 1179 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 1681 | 0.010 |
Why?
|
| Hair | 1 | 1996 | 42 | 0.010 |
Why?
|
| Lipase | 1 | 1997 | 112 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1997 | 318 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1996 | 141 | 0.010 |
Why?
|
| Area Under Curve | 1 | 1998 | 700 | 0.010 |
Why?
|
| Placebos | 1 | 1996 | 437 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2000 | 1914 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 3639 | 0.010 |
Why?
|
| Sex Factors | 1 | 2000 | 2139 | 0.010 |
Why?
|
| Syndrome | 1 | 1998 | 1351 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 915 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1994 | 79 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1994 | 49 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 58 | 0.010 |
Why?
|
| Androgens | 1 | 1997 | 511 | 0.010 |
Why?
|
| Child | 1 | 2014 | 29154 | 0.010 |
Why?
|
| Magnesium | 1 | 1994 | 160 | 0.010 |
Why?
|
| Neuromuscular Diseases | 1 | 1994 | 63 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 1998 | 1021 | 0.010 |
Why?
|
| Hypotension | 1 | 1994 | 210 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1999 | 882 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 2422 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1996 | 2588 | 0.010 |
Why?
|
| Salmonella paratyphi A | 1 | 1986 | 2 | 0.000 |
Why?
|
| Salmonella typhi | 1 | 1986 | 15 | 0.000 |
Why?
|
| Salmonella enteritidis | 1 | 1986 | 7 | 0.000 |
Why?
|
| Dysgerminoma | 1 | 1986 | 42 | 0.000 |
Why?
|
| Salmonella typhimurium | 1 | 1986 | 70 | 0.000 |
Why?
|
| Brain Abscess | 1 | 1986 | 60 | 0.000 |
Why?
|
| Meningitis | 1 | 1986 | 112 | 0.000 |
Why?
|
| Intracranial Pressure | 1 | 1986 | 180 | 0.000 |
Why?
|
| Craniocerebral Trauma | 1 | 1986 | 130 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1986 | 529 | 0.000 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1998 | 5319 | 0.000 |
Why?
|
| Infant | 1 | 1986 | 13310 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1986 | 16273 | 0.000 |
Why?
|